Re-Educating the Immune System: a ‘Brave New World’ in Immunology

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Re-Educating the Immune System: a ‘Brave New World’ in Immunology</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field."> <meta property="og:title" content="Re-Educating the Immune System: a ‘Brave New World’ in Immunology"> <meta name="twitter:description" content="RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field."> <meta name="twitter:title" content="Re-Educating the Immune System: a ‘Brave New World’ in Immunology"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hubfs/hub_generated/template_assets/1/135726131582/1735927837648/template_main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>   <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; var hsLoadGtm = function loadGtm() { if(window._hsGtmLoadOnce) { return; } if (useGoogleConsentModeV2) { gtag('set','developer_id.dZTQ1Zm',true); gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); _hsp.push(['useGoogleConsentModeV2']) } (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-P24V56ST'); window._hsGtmLoadOnce = true; }; _hsp.push(['addPrivacyConsentListener', function(consent){ if(consent.allowed || (consent.categories && consent.categories.analytics)){ hsLoadGtm(); } }]); </script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/re-educating-the-immune-system-a-brave-new-world-in-immunology"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_419130570-scaled.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_419130570-scaled.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/re-educating-the-immune-system-a-brave-new-world-in-immunology"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-P24V56ST" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/biologics-us-2025" class="pill center"> <div class="b">Biologics US 2025</div> <div class="heading-smallcaps"> Oct 2 - 3 2025 | San Diego, CA </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11 - 12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Reduce%20Your%20Supply%20Chain%20Risk%20with%20Proteomix%20POR-Q/S:%20Reliable%20Resins%20for%20IEX" class="cta" target="_blank"> <h3 class="other-resources">10/03/25 - Reduce Your Supply Chain Risk with Proteomix POR-Q/S: Reliable Resins for IEX</h3> </a> </div> <div class="top-divider"></div>  <div class="online-activity"> <a href="/nextgen-biomed/online#Innovative%20Contamination%20Control%20in%20Cell%20Therapy:%20Enabling%20Integrity%20and%20Efficiency" class="cta" target="_blank"> <h3 class="other-resources">25/03/25 - Innovative Contamination Control in Cell Therapy: Enabling Integrity and Efficiency</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/best-practice-ebook/advanced-instruments/optimising-cell-culture-by-tackling-translational-barriers-through-automation-and-3d-models"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/Optimising%20Cell%20Culture%20eBook%20Mock%20Up%20500px.png" class="sponsor-resource-bubble-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimising Cell Culture by Tackling Translational Barriers Through Automation and 3D Models </h3> <div class="resource-abstract"> Explore how industry experts and top academics are addressing shortcomings of traditional cell culture </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Immunotherapy (Non-Oncology) | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Re-Educating the Immune System: a ‘Brave New World’ in Immunology </h1> <div class="byline"> Edited by Tom Cohen | 24 March 2022 </div> <div class="abstract"> RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_419130570-scaled.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p></p> <p>The range of available therapies for patients with autoimmune diseases has long been limited to immune inhibitors. Those drugs have helped treat the symptoms of autoimmune diseases in some patients. However, they often have issues with resistance, effectiveness, and the side effects of suppressing a patient’s immune system.</p> <p></p> <p></p> <p>Some scientists have begun to question whether there might be a more effective answer to autoimmunity. The holy grail would be a solution that could cure these diseases rather than just mitigate their worst effects. That would mean an increase in remission rates while simultaneously removing the dangerous side-effects of immunosuppressors.</p> <p></p> <p></p> <p>Roly Foulkes is the Chief Scientific Officer at RevoloBio, a company asking that exact question. His company is working on “resetting” the immune system rather than simply suppressing it. Foulkes laid out RevoloBio’s pioneering project at <a href="https://www.oxfordglobal.co.uk/immuno-series-uk/">Oxford Global’s 2021 Immuno UK conference</a>.</p> <p></p> <p></p> <p>RevoloBio is taking a new approach to treating autoimmune diseases. Foulkes claims that they can induce long-term remission in patients by “resetting” or “re-educating” the immune system. Uniquely, only from a single dose of their new drug, ‘1805.</p> <p></p> <p></p> <p>The immunosuppressant drugs that have been the go-to for patients with autoimmune diseases work by inhibiting immune systems that problematically attack their own body. “Re-education” means that you teach the immune system to do its conventional purpose instead of simply inhibiting it.</p> <p></p>  <h2>‘1805: A Drug to Re-Educate the Immune System</h2>   <p>Foulkes explained that there is no need to chronically prescribe their drug due to its unique PD/PK effect of inducing regulatory T-cells. Preclinical studies, therefore, only looked at a single administration of ‘1805.</p>   <p>‘1805 is a first-in-class analogue of the endogenous binding immunoglobulin protein (BiP). BiP is mainly responsible for folding proteins and polypeptides, residing in the endoplasmic reticulum. Foulkes explains that BiP can also have immunoregulatory and anti-inflammatory properties under stressed conditions such as extracellular secretion.</p>   <p>These are the properties that RevoloBio exploit as the mode of action in their drug. RevoloBio has modified BiP to remove its intercellular properties and shown that its serum half-life is likely to be only around four hours in humans.</p>   <p>Therefore, the long-term beneficial effects of ‘1805 are due to an increased secretion of anti-inflammatory cytokines, reduction in pro-inflammatory cytokines, and also an affect the maturation of dendritic cells to induce regulatory phenotypes which leads to the generation of regulatory T-cells.</p>   <ul><li><a href="https://oxfordglobal.com/immuno/resources/t-cell-engagement-and-redirection-strategies-methods-and-t-cell-design/" target="_blank" rel="noreferrer noopener">T Cell Engagement and Redirection – Strategies, Methods, and T Cell Design</a></li></ul>   <p></p>   <h2>Applications and Challenges</h2>   <p>RevoloBio sees ‘1805 as having the potential to treat a range of autoimmune diseases. Still, at the moment, they are focussing on its application for patients with severe rheumatoid arthritis (RA) and uveitis. RA is a disease that has traditionally had a shallow remission rate, and the therapeutics on offer have been immunosuppressors that carry a serious risk of infection and other complications.</p>   <p>This is why the data from ‘1805’s Phase II clinical trial has been a step forward. The data suggests that the drug has shown safety in human studies and has the potential to produce rapid onset sustained remission in RA patients after a single dose.</p>   <p>Paul Eggleton, the Senior Director of Immunology at RevoloBio, called the shift toward re-educating the immune system a “<em>Brave New World</em>” in treating autoimmunity. However, Eggleton said the difficulty with this shift is that it is outside the comfort zone of many pharma companies.</p>   <p>Eggleton wants to encourage the change in mindset that RevoloBio is spearheading to spread industry-wide. He says that the future of therapeutics for autoimmune diseases requires targeting multiple immune pathways simultaneously, rather than antagonising single target pathways as has been standard in the past.</p>   <blockquote class="wp-block-quote is-style-large"><p>“In my view, the pharma industry is evolving and developing therapeutics that are more complex because we cannot eradicate such diseases by a ‘one-hit’ pathway. This, I believe, is the way forward.”</p></blockquote>   <h2 id="h-the-future-of-treating-autoimmune-disease">The Future of Treating Autoimmune Disease</h2>   <p>At Immuno UK 2021, Eggleton commented on where he thinks the vanguard of immunology might go next. He believes that neurodegenerative diseases look like “one of the final challenges of medicine.”</p>   <p>Neurodegenerative autoimmune diseases such as progressive multiple sclerosis are notoriously intractable. This makes the pathways toward better treatments of autoimmune disorders truly exciting.</p>   <ul><li><a href="https://oxfordglobal.com/immuno/resources/inhalation-products-addressing-unmet-needs/" target="_blank" rel="noreferrer noopener">Inhalation Products: Addressing Unmet Needs</a></li></ul>   <p></p>   <p>The lessons that RevoloBio is learning from their studies into RA and uveitis could prove to be useful in the broader battle against autoimmunity. Want to know more? Oxford Global is hosting a discussion led Eggleton on <strong>4 April at 15:00 (BST)</strong>.</p>   <p>The discussion group will focus on <em>‘Treating Autoimmune Diseases: Past, Present, and Future’</em> and will be a fantastic opportunity to network and share ideas. <a href="https://us02web.zoom.us/meeting/register/tZEscuuhpjsoHdHLtD4PspCuO1KmRgm05EbW">Click here to sign up for this exclusive event.</a></p>   <p>Want to see prominent experts and industry leaders in immunology in person? We recommend joining our upcoming <a href="https://oxfordglobal.com/immuno-series-uk/">Immuno UK conference</a>, the foremost hub of knowledge for immunology and immunotherapy.</p>  <div class="content-body-footer"> <div class="author-info text-no-gap"> <div class="author-about"> <h3> Speaker Biographies </h3> <p><strong>Dr. Roly Foulkes</strong> has 25 years of experience building and delivering innovative therapeutic portfolios within the immunology and inflammatory disease space. He has a strong record advising small and medium sized immunology biopharma companies in developing competitive therapeutic strategies and bringing new innovative molecules to the clinic.</p> </div> </div> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/sponsored/webinar/sino-biological/advancing-immunotherapy-the-critical-role-of-gmp-grade-cytokines-in-cell-therapy"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/NextGen%20Biomed%202025/SP%20webinar/Ritwika%20Biswas%20-%20Contetn%20Portal%20Image.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/sponsored/webinar/sino-biological/advancing-immunotherapy-the-critical-role-of-gmp-grade-cytokines-in-cell-therapy"> <h4> Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy </h4> <div class="abstract"> On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological </div> <div class="read-more"> <a href="/nextgen-biomed/resources/sponsored/webinar/sino-biological/advancing-immunotherapy-the-critical-role-of-gmp-grade-cytokines-in-cell-therapy" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus"> <h4> University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus </h4> <div class="abstract"> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/Clesrovimab%20Shows%20Positive%20Results%20as%20Preventative%20Treatment%20for%20RSV%20in%20Pre-Term%20and%20Full-Term%20Infants.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants"> <h4> Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants </h4> <div class="abstract"> The phase IIb/III met both its primary and secondary endpoints in infants one year old or younger. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1734435846962/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/re-educating-the-immune-system-a-brave-new-world-in-immunology"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999221"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999221", "legacyPageId": "hubdb-177607186815-30817717-181072999221", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "e929636f-058a-4c50-bd3e-25cebc5e1083", ticks: 1739773454051, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999221", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999221", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.393/js/index.js"></script> </body></html>

CINXE.COM

Re-Educating the Immune System: a ‘Brave New World’ in Immunology